Journal Article

Key Issues for a Potential Human Immunodeficiency Virus Vaccine

Bruce Gellin, John F. Modlin, Dale J. Hu, Charles R. Vitek, Bradford Bartholow and Timothy D. Mastro

in Clinical Infectious Diseases

Published on behalf of Infectious Diseases Society of America

Volume 36, issue 5, pages 638-644
Published in print March 2003 | ISSN: 1058-4838
Published online March 2003 | e-ISSN: 1537-6591 | DOI: http://dx.doi.org/10.1086/367891
Key Issues for a Potential Human Immunodeficiency Virus Vaccine

More Like This

Show all results sharing these subjects:

  • Infectious Diseases
  • Immunology
  • Public Health and Epidemiology
  • Microbiology

GO

Show Summary Details

Preview

A safe, effective, and affordable vaccine remains the best long-term hope for bringing the global human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) epidemic under control. Recent scientific developments have suggested that the first generation of HIV vaccines available for public health care use will likely be of low to moderate efficacy, compared with currently licensed vaccines for other diseases. Nevertheless, such “partially effective ”HIV vaccines could provide considerable individual and public health benefits. A consultation was held in January 2002 to advise the Centers for Disease Control and Prevention (Atlanta, Georgia) about critical issues that need to be addressed in anticipation of the eventual licensure and availability of an HIV vaccine in the United States. The present article summarizes the major issues discussed at the consultation with regard to the potential use of a partially effective vaccine in HIV prevention programs in the United States and the activities that are needed to prepare for vaccine availability.

Journal Article.  5262 words. 

Subjects: Infectious Diseases ; Immunology ; Public Health and Epidemiology ; Microbiology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.